- Home
- REGN vs CB Comparison
REGN vs CB Comparison
Compare REGN & CB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | REGN | CB |
|---|---|---|
| Founded | 1988 | 1985 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.4B | 129.7B |
| IPO Year | 1995 | 1995 |
Fundamental Metrics
Financial Performance| Metric | REGN | CB |
|---|---|---|
| Price | $759.58 | $326.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 19 |
| Target Price | ★ $815.04 | $332.00 |
| AVG Volume (30 Days) | 638.2K | ★ 1.5M |
| Earning Date | 04-16-2026 | 01-01-0001 |
| Dividend Yield | 0.49% | ★ 1.17% |
| EPS Growth | 8.19 | ★ 13.13 |
| EPS | ★ 41.48 | 25.68 |
| Revenue | $5,872,227,000.00 | ★ $59,402,000,000.00 |
| Revenue This Year | $11.69 | N/A |
| Revenue Next Year | $10.12 | $5.31 |
| P/E Ratio | $18.41 | ★ $12.98 |
| Revenue Growth | ★ 20.82 | 6.54 |
| 52 Week Low | $476.49 | $264.10 |
| 52 Week High | $821.11 | $345.67 |
Technical Indicators
Market Signals| Indicator | REGN | CB |
|---|---|---|
| Relative Strength Index (RSI) | 45.70 | 49.17 |
| Support Level | $740.39 | $322.43 |
| Resistance Level | $786.67 | $335.60 |
| Average True Range (ATR) | 21.54 | 5.53 |
| MACD | -2.98 | -1.36 |
| Stochastic Oscillator | 18.91 | 19.97 |
Price Performance
Historical ComparisonAbout REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About CB Chubb Limited
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination made the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.